Population Pharmacokinetics and Exposure‐Response of Subcutaneous Atezolizumab in Patients With Non‐Small Cell Lung Cancer

ABSTRACT IMscin001 is a two‐part dose‐finding (Phase Ib) and ‐confirmation (Phase III) study to evaluate atezolizumab pharmacokinetics of subcutaneous (SC) compared with intravenous (IV) administration in patients with locally advanced or metastatic non‐small cell lung cancer (NSCLC). The objectives...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Phyllis Chan, Stephanie N. Liu, Nathalie Gosselin, Zacharie Sauve, Mathilde Marchand, Alyse Lin, Luis Herraez‐Baranda, James Zanghi, Esther Shearer‐Kang, Xiaoyan Liu, Benjamin Wu, Pascal Chanu
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Wiley 2025-04-01
Serie:	CPT: Pharmacometrics & Systems Pharmacology
Accesso online:	https://doi.org/10.1002/psp4.13310
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!